Jim Cramer on GRAIL: "I'm Going to Say Absolutely Not to That One"

GRAIL, Inc. (NASDAQ:GRAL) is one of the stocks Jim Cramer recently answered questions about. Responding to a caller’s question about the stock during the lightning round, Cramer remarked:

“Yeah, and I just read a really good piece the other day written by Dr. Topol, who’s been on the show a number of times. It did not make me feel that it was worth a, you know, I just didn’t think it was worth owning after this very big parabolic move. I’m going to say absolutely not to that one.”

GRAIL, Inc. (NASDAQ:GRAL) develops and markets blood-based tests for early cancer detection, including its Galleri screening test for multiple cancers. On October 17, it announced positive results from its PATHFINDER 2 study of the Galleri multi-cancer early detection test. The study included 35,878 adults, and it showed that adding Galleri to standard screenings increased cancer detection more than seven-fold, with over half of the detected cases found at early stages, and about three-quarters of the cancers detected by Galleri lack existing screening options.

In addition, Galleri demonstrated 99.6% specificity, a 0.4% false positive rate, and correctly identified the cancer’s origin 92% of the time. There were no serious study-related adverse events, and GRAIL, Inc. (NASDAQ:GRAL) is planning to submit the data to the FDA for premarket approval in the first half of 2026.

While we acknowledge the potential of GRAL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.